Drug-tolerant cells, which are also referred to as drug-tolerant persisters, have also been found for other targeted therapeutic treatments such as those for BRAF-mutant melanoma [2], androgen-receptor-driven prostate cancer [3], and HER2-amplified breast cancer [4], as well as chemotherapy [5]. This evidence concerns the gene ERBB2 and breast carcinoma.